These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16524070)

  • 1. [Non-myeloablative transplant of hematopoietic precursor cells. Myth and reality].
    Gómez-Almaguer D; Ruiz-Argüelles GJ; Gutiérrez-Aguirre CH; Jaime-Pérez JC
    Rev Invest Clin; 2005; 57(2):291-7. PubMed ID: 16524070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
    Resnick IB; Shapira MY; Slavin S
    Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges.
    Satwani P; Harrison L; Morris E; Del Toro G; Cairo MS
    Biol Blood Marrow Transplant; 2005 Jun; 11(6):403-22. PubMed ID: 15931629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Transplant of hemopoietic progenitors].
    Rifón JJ
    An Sist Sanit Navar; 2006; 29 Suppl 2():137-51. PubMed ID: 16998522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor.
    Magro E; Regidor C; Cabrera R; Sanjuán I; Forès R; Garcia-Marco JA; Ruiz E; Gil S; Bautista G; Millán I; Madrigal A; Fernandez MN
    Haematologica; 2006 May; 91(5):640-8. PubMed ID: 16670070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
    Foss FM
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
    Pollack SM; O'Connor TP; Hashash J; Tabbara IA
    Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
    Giralt S
    Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post transplant persistence of host cells augments the intensity of acute graft-versus-host disease and level of donor chimerism, an explanation for graft-versus-host disease and rapid displacement of host cells seen following non-myeloablative stem cell transplantation?
    Hirshfeld E; Weiss L; Kasir J; Zeira M; Slavin S; Shapira MY
    Bone Marrow Transplant; 2006 Sep; 38(5):359-64. PubMed ID: 16862165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.
    Huugen D; Schouten HC; Bos GM
    Neth J Med; 2002 May; 60(4):162-9. PubMed ID: 12164394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multicenter report of nonmyeloablative allogeneic stem cell transplantation for hematologic diseases].
    Ai HS; Huang XJ; Qiao ZH; Wang JM; Chen BA; Bai H; Shi BF; Liang YM; Sun WJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):505-8. PubMed ID: 19954634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy--from bench to patient bedside.
    Slavin S; Morecki S; Weiss L; Shapira MY; Resnick I; Or R
    Semin Oncol; 2004 Feb; 31(1):4-21. PubMed ID: 14970932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
    Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
    Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
    Alousi A; de Lima M
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):560-70. PubMed ID: 17679930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.